Related Experiment Videos
FDG-PET in adrenocortical carcinoma
A Becherer1, H Vierhapper, C Pötzi
1Department of Nuclear Medicine, University of Vienna, Austria. alexander.becherer@univie.ac.at
Cancer Biotherapy & Radiopharmaceuticals
|October 18, 2001
Summary
Fluorodeoxyglucose-positron emission tomography (FDG-PET) is highly effective for detecting adrenal cortical carcinoma (ACC) recurrence. This imaging technique aids in accurate staging and influences treatment decisions for ACC patients.
Area of Science:
- Oncology
- Nuclear Medicine
- Diagnostic Imaging
Background:
- Adrenal cortical carcinoma (ACC) is a rare cancer with a poor prognosis.
- Radical surgery is the primary treatment, necessitating precise localization of recurrent tumors.
Purpose of the Study:
- To evaluate the utility of FDG-PET in the staging and follow-up of patients with ACC.
- To determine the sensitivity and specificity of FDG-PET for detecting ACC lesions.
Main Methods:
- Prospective study of 10 patients with ACC (8 during follow-up, 2 at initial work-up).
- Whole-body FDG-PET scans were performed 45 minutes after [18F]FDG injection.
- Image interpretation was conducted visually, blinded to other diagnostic results.
Main Results:
- FDG-PET demonstrated high uptake in all known ACC lesions.
- Previously undetected lesions were identified in the lung, abdomen, and skeleton in 3 patients.
- Overall sensitivity and specificity for PET were 100%/97% (organ-based) and 100%/95% (lesion-based).
- PET altered tumor staging in 30% of patients and influenced therapeutic management in 20%.
Conclusions:
- FDG-PET is a highly valuable tool for the initial staging and follow-up of adrenal cortical carcinoma.
- Incorporating FDG-PET into the management of ACC can significantly improve diagnostic accuracy and treatment planning.